Immunotherapy-related hepatitis: real-world experience from a tertiary centre
<p><strong>Objective</strong> Immune checkpoint inhibitors like anti-programmed cell death protein 1 (PD-1) drugs Nivolumab and Pembrolizumab and anti-cytotoxic T-lymphocyte associated (CTLA-4) drug Ipilimumab have become standard of care in many metastatic cancers. Immunotherapy-r...
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 出版: |
BMJ Publishing Group
2019
|